Myovant sciences ltd. (MYOV)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net Loss

-64,900

-85,600

-70,600

-67,900

-75,014

-70,633

-65,770

-62,134

-48,253

-41,777

-29,908

-23,317

-21,674

-8,083

-34,713

-18,970

-1,657

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

6,073

19,795

7,931

6,452

4,933

4,794

4,725

4,244

3,340

3,293

2,749

2,201

1,936

2,010

2,150

2,621

1,434

Depreciation and amortization

529

510

370

356

140

107

100

91

76

63

54

50

52

8

1

0

0

Amortization of debt discount and issuance costs

0

391

540

555

706

442

429

507

272

390

0

0

-

-

-

-

0

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

13,117

0

Changes in the fair value of the Takeda warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-1,297

-1,002

27,985

1,832

0

Foreign currency translation adjustment

-

-

-

-

-

-

-

-

-

379

116

-264

-

0

0

0

0

Other items

806

805

-344

713

-436

-234

-140

-425

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-3,817

2,117

1,276

-1,501

-2,180

3,995

2,677

563

-140

1,541

-1,444

1,961

2,068

1,115

38

0

0

Deferred tax assets

-

-

-

-

-

-

-

-

0

0

0

-208

208

0

0

0

0

Income tax receivable

0

17

314

193

243

0

88

145

-393

-502

0

0

-

-

-

-

-

Other assets

-262

-527

1,036

-237

-222

50

384

-288

967

0

-976

3,074

-100

0

100

0

0

Accounts payable

-

-

-4,185

-1,015

-

-

3,392

389

2,487

737

-1,832

-143

2,780

179

370

0

0

Income tax payable

-

-

-

-

-

-

-

-

-

-

-265

826

-

-

1

0

-

Interest payable

0

-305

-453

-319

648

129

-72

90

282

0

0

0

-

-

-

-

0

Accrued expenses

-16,154

904

-1,736

-7,568

5,270

9,903

136

8,040

9,449

6,269

3,255

-686

8,843

1,869

799

244

223

Operating lease liabilities

-335

-179

-190

-178

-

-

-

-

-

-

-

-

-

-

-

-

-

Due to former majority shareholder

0

-271

75

75

55

-512

-4,629

3,247

-1,723

2,952

-1,269

-1,030

708

-713

2,861

1,153

0

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-105

-

0

3

-3

0

Deferred interest payable

0

-5,323

1,533

1,517

1,500

213

153

152

150

105

0

0

-

-

-

-

0

Net Cash Provided by (Used in) Operating Activities

-19,300

-66,800

-68,300

-66,800

-53,108

-62,099

-64,126

-44,755

-34,989

-30,905

-24,804

-26,557

-10,665

-6,863

-687

0

0

Cash flows from investing activities:
Purchases of property and equipment

275

292

393

139

518

328

193

197

229

218

67

90

598

369

0

0

0

Net cash used in investing activities

12,525

11,232

-27,553

-139

-518

-328

-193

-197

-229

-218

-67

-90

-598

-369

0

0

0

Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Initial public offering costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common shares, net of issuance costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from stock option exercises

275

353

0

314

529

305

390

76

20

4

12

0

-

-

-

-

0

Cash proceeds from debt financings, net of financing costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash capital contribution from RSL

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Settlement of former majority shareholder common shares subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Due to RSL and RSI for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

275

8,263

-222

137,610

27,222

91,713

75,001

79,963

14,969

30,664

12

0

-221

199,481

760

0

0

Net change in cash, cash equivalents and restricted cash

-6,429

-47,300

-96,112

70,660

-26,404

29,286

10,682

35,011

-20,249

-459

-24,859

-26,647

-11,484

192,249

73

0

0

Non-cash financing activities:
Deferred financing costs included in accrued expenses

-

-70

-142

212

-

-266

220

72

-

-

-

-

-

-

-

-

-

Offering costs, unpaid included in accrued expenses

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Deferred initial public offering costs, unpaid

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,383

1,079

524

-

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

13,117

0

Warrants issued to Hercules

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of cash paid:
Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Public Equity Offering
Proceeds from issuance of common shares, net of issuance costs paid

0

-70

-222

134,750

0

-292

74,683

0

-

-

-

-

-

-

-

-

-